Loading
REGENXBIO Inc. Stock: price and insider trades · United States
1 insider bought €814k of shares over the last 90 days, the latest by Ciongoli Gregory Austin, filed 27 Aug 2026.
REGENXBIO Inc.: what insiders have been doing
REGENXBIO Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 9 insiders have disclosed 28 filings since 22 October 2025.
The record shows 2 purchases on the open market worth €814k, made by 1 insider, against 2 sales worth €71k by 1 insider. Purchases outweigh sales by €742k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. At €429k, the purchase published on 27 August 2026 by Ciongoli Gregory Austin is the largest of the period (0.10% of market cap). The buyers include 1 senior executive.
The latest purchase dates back some time: it was published 58 days ago, on 27 August 2026. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4.
For context, the typical company on the same exchange (median of 3,171 companies) published 24 filings over the same period, against 28 filings here. Over the whole record (from 2016), the tally stands at 2 purchases and 434 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 170.4 m USD and net income at -193.9 m USD.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
740
Thresholds
n/a
Buy Volume
€813,740
2 ops. · all time
Sell Volume
€89M
434 ops. · all time
Who traded when
BuySaleCurran Simpson3 sales
Gregory Austin Ciongoli2 buys
Steve Pakola2 sales
Kenneth T. Mills1 sale
Since the insiders bought
- -28.0%Entry US$9.66 · Close 16 Oct 2026 US$6.96
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate REGENXBIO Inc. Buy (bullish), based on 12 analysts. Average price target: US$23.58.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,003 of 26,280 companies
27.6
score / 100
Value7
Quality48
FCF yld-27%
Earn yld-41%
EV/EBITDA·
ROE-138%
Gross mgn88%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.15
Analyst consensus
12 analystsBuy
US$10.00Target US$23.58(+230%)US$50.00
Income statement
RevenueUS$170.4M
Gross profitUS$150.1M88% margin
EBITDA-US$133.3M-78% margin
Net income-US$193.9M-112.6% margin
Valuation
PER (forward)-2.4x
P/Book5.4x
Beta1.13
Balance sheet & cash
Market capUS$472M
Total debtUS$73.5M
Free Cash Flow-US$126.4M
Debt / Equity349%
Profitability & ownership
ROE-137.6%
ROA-21.2%
% insiders6.5%
% institutions65.1%
Last declaration on 3 September 2026
Declarations740 total
234 shares@ US$9.320.0004% mcap10.0% of flowCommon StockSEC:0002062007-26-000005:0
4,902 shares@ US$9.320.0094% mcap51.3% of flowCommon StockSEC:0001789335-26-000008:0
15,432 shares0Common StockSEC:0002023732-26-000008:0
49,196 shares@ US$9.14110.092% mcap47.3% of flowCommon StockSEC:0002023732-26-000008:1
Canonical exit: 24 Nov 2026 (T+90)
53,407 shares@ US$9.3560.10% mcap52.7% of flowCommon StockSEC:0002023732-26-000008:2
Canonical exit: 25 Nov 2026 (T+90)
7,468 shares@ US$9.690.015% mcap5.9% of flowCommon StockSEC:0001700659-26-000016:0
4,699 shares@ US$9.690.0094% mcap7.0% of flowCommon StockSEC:0001521123-26-000008:0
2,161 shares@ US$7.860.0035% mcap1.4% of flowCommon StockSEC:0001700659-26-000014:0
2,161 shares@ US$13.640.0061% mcap2.4% of flowCommon StockSEC:0001700659-26-000014:1
951 shares@ US$6.99550.5% of flowCommon StockSEC:0001346164-26-000006:0
1,453 shares@ US$10.180.0031% mcap1.1% of flowCommon StockSEC:0001346164-26-000006:1
6,818 shares@ US$13.090.019% mcap6.8% of flowCommon StockSEC:0001346164-26-000006:2
43,206 shares@ US$11.980.11% mcap100.0% of flowCommonSEC144:0001950047-26-006719
9,807 shares0Common StockSEC:0001872219-26-000001:0
5,124 shares@ US$10.354.3% of flowCommon StockSEC:0001700659-26-000008:0
5,267 shares@ US$11.164.6% of flowCommon StockSEC:0001700659-26-000006:0
4,700 shares@ US$11.167.8% of flowCommon StockSEC:0001521123-26-000006:0
221,753 shares@ US$13.418.5% of flowCommon StockSEC:0001652824-26-000002:1
225,000 shares@ US$13.0965.9% of flowCommon StockSEC:0001652824-26-000002:0
65,847 shares0Common StockSEC:0002062007-26-000003:0
73,749 shares0Common StockSEC:0001789335-26-000002:0
65,847 shares0Common StockSEC:0001700659-26-000004:0
73,749 shares0Common StockSEC:0001521123-26-000004:0
144,864 shares0Common StockSEC:0001346164-26-000004:0
1,238 shares@ US$14.4080.6% of flowCommon StockSEC:0002062007-26-000002:0
25 of 740 declarations
About REGENXBIO Inc.
REGENXBIO Inc. is a U.S.-based biotechnology company listed on the Nasdaq market in the United States, focused on in vivo gene therapy. Headquartered in Rockville, Maryland, the company develops treatments intended to address severe genetic and degenerative diseases, with a particular emphasis on rare diseases and retinal disorders. Its core competitive asset is its proprietary NAV Technology platform, designed to support AAV-based gene delivery and durable therapeutic expression. Founded in 2009, REGENXBIO has evolved into a recognized gene-therapy developer through a mix of internal R&D and strategic pharmaceutical partnerships. ([ir.regenxbio.com](https://ir.regenxbio.com/?utm_source=openai))
The company’s pipeline is centered on several clinical and pre-commercial programs. The most advanced asset is RGX-202, a gene therapy candidate for Duchenne muscular dystrophy. In 2025 and 2026, REGENXBIO reported encouraging interim data, completed pivotal enrollment, and began commercial production activities, with top-line pivotal data expected in early Q2 2026 and a BLA filing targeted for mid-2026. In rare lysosomal diseases, the company is developing RGX-121 for MPS II and RGX-111 for MPS I through a partnership with Nippon Shinyaku. In ophthalmology, REGENXBIO is advancing ABBV-RGX-314 with AbbVie for wet AMD and diabetic retinopathy. ([ir.regenxbio.com](https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-completion-pivotal-enrollment-and-initiates/?utm_source=openai))
Read moreShow less
From a commercial perspective, REGENXBIO is still largely a development-stage company, but its risk-reward profile has improved as its lead programs move closer to potential approval. Its competitive positioning is built on a combination of proprietary platform know-how, integrated manufacturing capabilities, and a pipeline aimed at high-unmet-need indications. The company manufactures RGX-202 at its Manufacturing Innovation Center in Rockville, which strengthens supply-chain control and could support future launch readiness. ([ir.regenxbio.com](https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-completion-pivotal-enrollment-and-initiates/?utm_source=openai))
Geographically, REGENXBIO remains primarily U.S.-anchored, with headquarters, research, and manufacturing operations in the United States, while its partnerships broaden potential commercialization into international markets. Agreements with AbbVie and Nippon Shinyaku extend the company’s reach and validate its technology platform. Recent highlights include continued positive data for RGX-202, ongoing regulatory progress for RGX-121, and manufacturing scale-up tied to a possible mid-2026 launch path. For European investors, this is a high-upside biotech name, but one that remains highly dependent on clinical execution, regulatory decisions, and eventual market adoption. ([ir.regenxbio.com](https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-reports-new-positive-interim-data-phase-iii-affinity/?utm_source=openai))
